AUTISM SPECTRUM DISORDER THERAPEUTICS MARKET ANALYSIS

Autism Spectrum Disorder Therapeutics MarketSize and Trends

The global autism spectrum disorder therapeutics (ASD) therapeutics market size was valued at US$ 2,285.5 million in 2019, and is expected to witness a CAGR of 10.9% over the forecast period (2019 – 2027).

Global Autism Spectrum Disorder Therapeutics Market Share (%) Analysis, By Drug Type, 2019

Source: Coherent Market Insights Analysis (2019)

Increasing Number of Pipeline Drugs and Early Diagnosis of ASD is expected to Drive Growth of the Autism Spectrum Disorder Therapeutics Market

Increasing number of pipeline drugs and launches of novel products by key players are expected to be the major driving factors for the global autism spectrum disorder therapeutics market growth during the forecast period. For instance, in February 2014, the company was awarded six new patents for its enzyme delivery system in Europe, Australia, and Central America, which can be utilized for multiple enzyme products including CM-AT— Curemark’s proprietary ASD drug.

Furthermore, in September 2017, Curemark conducted second Phase III clinical trial: Blüm Study— to evaluate the safety and efficacy of CM-AT in children aged 3-8 with ASD.

Moreover, earlier diagnosis of ASD can aid in the development of children. For instance, according to the research published in the JAMA Pediatrics journal in April 2019, accurate diagnosis of ASD at earlier than 18 months is feasible and there may be opportunities to test the usefulness of ASD treatment at an early age. Therefore, increasing research on ASD is expected to create a favorable environment for autism spectrum disorder therapeutics market growth over the forecast period.